changing the treatment landscape
MYO_logo_TM_1

MYO Technology

Next-generation biologics to modernize and transform the monoclonal antibody and protein therapeutic fields

Group 2 Copy 2

Bispecific Antibodies

First- and Best-in-class engineered antibodies to significantly reduce the impact of diseases that could benefit from antibody therapeutics